Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Galderma Laboratories, L.P. |
---|---|
Information provided by: | Galderma Laboratories, L.P. |
ClinicalTrials.gov Identifier: | NCT00669071 |
This study is to evaluate the efficacy and safety of Tri-Luma® Cream (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%); TLC) when used sequentially with a series of intense pulsed light (IPL) treatments in Subjects diagnosed with moderate to severe melasma during a 10 week treatment period.
Condition | Intervention | Phase |
---|---|---|
Melasma |
Drug: Fluocinolone acetonide .01%, hydroquinone 4%, tretinoin .05% Drug: Inactive Control Cream |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Single Blind (Outcomes Assessor), Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | Split-Face, Randomized, Open-Label Study of Sequential Treatment With Tri-Luma® Cream With Intense Pulsed Light vs. a Mild Inactive Control Cream With Intense Pulsed Light in Subjects With Melasma |
Enrollment: | 56 |
Study Start Date: | December 2007 |
Study Completion Date: | October 2008 |
Primary Completion Date: | October 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1
Single arm study
|
Drug: Fluocinolone acetonide .01%, hydroquinone 4%, tretinoin .05%
Applied once daily at bedtime on one side of the face
Drug: Inactive Control Cream
Applied once daily at bedtime on the opposite side of the face
|
Same as above.
Ages Eligible for Study: | 18 Years to 74 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Dermatology/Cosmetic Laser Associates of La Jolla, Inc. | |
LaJolla, California, United States, 92037 | |
United States, Tennessee | |
Tennessee Clinical Research Center | |
Nashville, Tennessee, United States, 37215 |
Study Director: | Ron W Gottschalk, MD | Galderma Laboratories, L.P. |
Responsible Party: | Galderma Laboratories, L.P. ( Ronald W. Gottschalk, MD / Medical Director ) |
Study ID Numbers: | US10081 |
Study First Received: | April 24, 2008 |
Last Updated: | November 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00669071 |
Health Authority: | United States: Institutional Review Board |
Hyperpigmentation Skin Diseases Facies Fluocinolone Acetonide |
Pigmentation Disorders Hydroquinone Tretinoin Melanosis |
Anti-Inflammatory Agents Therapeutic Uses Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists |
Hormones Glucocorticoids Pharmacologic Actions |